Galera Therapeutics (NASDAQ:GRTX) Stock Price Up 7.4%

Galera Therapeutics, Inc. (NASDAQ:GRTX) rose 7.4% on Tuesday . The stock traded as high as $0.14 and last traded at $0.14. Approximately 218,936 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 1,845,000 shares. The stock had previously closed at $0.13.

Galera Therapeutics Stock Down 3.6 %

The firm has a market cap of $7.29 million, a PE ratio of -0.14 and a beta of 1.98. The firm has a 50-day moving average price of $0.15 and a two-hundred day moving average price of $0.17.

Galera Therapeutics (NASDAQ:GRTX) last released its earnings results on Monday, May 13th. The company reported ($0.08) earnings per share for the quarter.

Institutional Investors Weigh In On Galera Therapeutics

An institutional investor recently bought a new position in Galera Therapeutics stock. abrdn plc purchased a new stake in Galera Therapeutics, Inc. (NASDAQ:GRTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 898,374 shares of the company’s stock, valued at approximately $131,000. abrdn plc owned about 1.65% of Galera Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 50.77% of the company’s stock.

Galera Therapeutics Company Profile

Galera Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy.